Seegene Expands Precision Diagnostics for Women’s Health
SEOUL, South Korea, July 27, 2026 Seegene Inc., a global leader in molecular diagnostics, has introduced a comprehensive syndromic...
cardiovascular disease
Advertisement
Alamar Biosciences Launches NULISAseq Immune 340 Panel
FREMONT, Calif., July 28, 2026 Alamar Biosciences, Inc. has announced the commercial launch of the NULISAseq™ Immune 340 Panel,...
Lexicon Pharmaceuticals Completes Enrollment in Phase 3 SONATA-HCM Trial
THE WOODLANDS, Texas, July 27, 2026 Lexicon Pharmaceuticals, Inc. announced the completion of patient enrollment and randomization in the...
AnX Robotica Unveils NaviCONNECT Cloud Platform for GI Diagnostics
PLANO, Texas, July 26, 2026 AnX Robotica has announced the commercial launch of NaviCONNECT™, a next-generation cloud platform designed...
NewAmsterdam Pharma Wins CHMP Support for Ubeslo® and Evlarco®
NAARDEN, The Netherlands; MIAMI, USA; and FLORENCE, Italy, July 24, 2026 NewAmsterdam Pharma and its commercialization partner Menarini Group...
Advertisements
Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
ArkBio Completes Phase I Dosing of AK0406 Influenza Drug
SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...
Lundbeck Wins FDA Fast Track for Lu AH69593 in Narcolepsy
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
Royalty Pharma Acquires Cliramitug Royalty Rights from Neurimmune
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
Advertisement
